Antimicrobial resistance: a global view from the 2013 World Healthcare-Associated Infections Forum

Antimicrobial Resistance and Infection Control

Angela Huttner³  Stephan Harbarth³  Jean Carlet⁴  Sara Cosgrove⁷  Herman Goossens²  Alison Holmes¹  Vincent Jarlier⁶  Andreas Voss⁵  Didier Pittet³ 

[1] Department of Infectious Diseases and Immunity, Imperial College London, The Centre for Infection Prevention and Management, London, UK

[2] Department of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium

[3] Infection Control Programme and WHO Collaborating Centre on Patient Safety, University Hospitals of Geneva, Rue Gabrielle-Perret-Gentil 4, 1205, Geneva, Switzerland

[4] Fondation Hôpital St Joseph, Paris, France

[5] Department of Medical Microbiology and Infection Control, Radboud University Nijmegen Medical Centre and Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands

[6] Laboratory of Bacteriology-Hygiene, Assistance Publique-Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Université Pierre et Marie Curie-Paris 6, Paris, France

[7] Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

关键词: World Healthcare-Associated Infections Forum;    Global health;    Animal medicine;    Human medicine;    Regulations;    Environment;    Care bundles;    Surveillance networks;    Hand hygiene;    Infection control;    Antibiotic stewardship;    Antimicrobial conservation;    Antimicrobial resistance;   

Others  :  790698
DOI  :  10.1186/2047-2994-2-31

 received in 2013-10-31, accepted in 2013-10-31,  发布年份 2013

【 摘 要 】

Antimicrobial resistance (AMR) is now a global threat. Its emergence rests on antimicrobial overuse in humans and food-producing animals; globalization and suboptimal infection control facilitate its spread. While aggressive measures in some countries have led to the containment of some resistant gram-positive organisms, extensively resistant gram-negative organisms such as carbapenem-resistant enterobacteriaceae and pan-resistant Acinetobacter spp. continue their rapid spread. Antimicrobial conservation/stewardship programs have seen some measure of success in reducing antimicrobial overuse in humans, but their reach is limited to acute-care settings in high-income countries. Outside the European Union, there is scant or no oversight of antimicrobial administration to food-producing animals, while evidence mounts that this administration leads directly to resistant human infections. Both horizontal and vertical infection control measures can interrupt transmission among humans, but many of these are costly and essentially limited to high-income countries as well. Novel antimicrobials are urgently needed; in recent decades pharmaceutical companies have largely abandoned antimicrobial discovery and development given their high costs and low yield. Against this backdrop, international and cross-disciplinary collaboration appears to be taking root in earnest, although specific strategies still need defining. Educational programs targeting both antimicrobial prescribers and consumers must be further developed and supported. The general public must continue to be made aware of the current scale of AMR’s threat, and must perceive antimicrobials as they are: a non-renewable and endangered resource.

【 授权许可】

   
2013 Huttner et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]D'Costa VM, King CE, Kalan L, Morar M, Sung WW, Schwarz C, et al.: Antibiotic resistance is ancient. Nature 2011, 477(7365):457-461.
• [2]Fleming A: Penicillin. Nobel Lecture, December 11, 1945. 1945. Available from: http://www.nobelprize.org/nobel_prizes/medicine/laureates/1945/fleming-lecture.pdf webcite
• [3]Penders J, Stobberingh EE, Savelkoul PH, Wolffs PF: The human microbiome as a reservoir of antimicrobial resistance. Front Microbiol 2013, 4:87.
• [4]USFDA: Summary Report on Antimicrobials Sold or Distributed for Use in Food-Producing Animals. 2009. Available from: http://www.fda.gov/downloads/ForIndustry/UserFees/AnimalDrugUserFeeActADUFA/UCM231851.pdf webcite
• [5]Laxminarayan R: Personal communication. 2013.
• [6]Patel G, Bonomo RA: "Stormy waters ahead": global emergence of carbapenemases. Front Microbiol 2013, 4:48.
• [7]Barber M, Rozwadowska-Dowzenko M: Infection by penicillin-resistant staphylococci. Lancet 1948, 2(6530):641-644.
• [8]Johnson AP, Davies J, Guy R, Abernethy J, Sheridan E, Pearson A, et al.: Mandatory surveillance of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in England: the first 10 years. J Antimicrob Chemother 2012, 67(4):802-809.
• [9]Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, et al.: Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007, 298(15):1763-1771.
• [10]Gastmeier PSC, Behnke M, Geffers C: Dramatic increase of vancomycin-resistant Enterococci in Germany with a belt of very high proportions [abstract]. France: 4th Biennial Healthcare-associated infections Forum Annecy; 2013.
• [11]Tseng SH, Lee CM, Lin TY, Chang SC, Chuang YC, Yen MY, et al.: Combating antimicrobial resistance: antimicrobial stewardship program in Taiwan. J Microbiol Immunol Infect 2012, 45(2):79-89.
• [12]Ziakas PD, Thapa R, Rice LB, Mylonakis E: Trends and significance of VRE colonization in the ICU: a meta-analysis of published studies. PloS one 2013, 8(9):e75658.
• [13]Brolund A, Edquist PJ, Makitalo B, Olsson-Liljequist B, Soderblom T, Tegmark Wisell K, et al.: Epidemiology of ESBL-producing Escherichia coli in Sweden 2007–2011. Clin Microbiol Infect 2013. doi: 10.1111/1469-0691.12413. [Epub ahead of print]
• [14]Colpan A, Johnston B, Porter S, Clabots C, Anway R, Thao L, et al.: Escherichia coli sequence type 131 (ST131) subclone H30 as an emergent multidrug-resistant pathogen among US veterans. Clin Infect Dis 2013, 57(9):1256-1265.
• [15]Reuland EA, Kostense P, et al.: Carriage of ESBL-producing enterobacteriaceae in the community and risk factors for carriage [abstract]. France: 4th Biennial World Healthcare-associated Infections Forum Annecy; 2013.
• [16]Reuland EA, Overdevest IT, Al Naiemi N, Kalpoe JS, Rijnsburger MC, Raadsen SA, et al.: High prevalence of ESBL-producing enterobacteriaceae carriage in Dutch community patients with gastrointestinal complaints. Clin Microbiol Infect 2013, 19(6):542-549.
• [17]Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP: Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Contr Hosp Epidemiol 2008, 29(12):1099-1106.
• [18]Walsh TR, Weeks J, Livermore DM, Toleman MA: Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis 2011, 11(5):355-362.
• [19]Allegranzi B, Bagheri Nejad S, Combescure C, Graafmans W, Attar H, Donaldson L, et al.: Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. Lancet 2011, 377(9761):228-241.
• [20]Bagheri Nejad S, Allegranzi B, Syed SB, Ellis B, Pittet D: Health-care-associated infection in Africa: a systematic review. Bull World Health Organ 2011, 89(10):757-765.
• [21]Centers for Disease Control and Prevention: Update to CDC's Sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep 2012, 61(31):590-594.
• [22]Ohnishi M, Golparian D, Shimuta K, Saika T, Hoshina S, Iwasaku K, et al.: Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother 2011, 55(7):3538-3545.
• [23]Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P: High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother 2012, 56(3):1273-1280.
• [24]Smith R, Coast J: The true cost of antimicrobial resistance. BMJ 2013, 346:f1493.
• [25]Smith R, Coast J: The economic burden of antimicrobial resistance: why it is more serious than current studies suggest [report]. London: London School of Hygiene & Tropical Medicine; 2012.
• [26]Macfarlane J, Holmes W, Macfarlane R, Britten N: Influence of patients' expectations on antibiotic management of acute lower respiratory tract illness in general practice: questionnaire study. BMJ 1997, 315(7117):1211-1214.
• [27]Lambert HP: Don't keep taking the tablets? Lancet 1999, 354(9182):943-945.
• [28]Pittet D, Allegranzi B, Boyce J: The world health organization guidelines on hand hygiene in health care and their consensus recommendations. Infect Contr Hosp Epidemiol 2009, 30(7):611-622.
• [29]Lee AS, Huttner B, Harbarth S: Control of methicillin-resistant Staphylococcus aureus. Infect Dis Clin North Amer 2011, 25(1):155-179.
• [30]van der Bij AK, Pitout JD: The role of international travel in the worldwide spread of multiresistant Enterobacteriaceae. J Antimicrob Chemother 2012, 67(9):2090-2100.
• [31]Harbarth S, Samore MH: Antimicrobial resistance determinants and future control. Emerg Infect Dis 2005, 11(6):794-801.
• [32]European Commission press releaseIP/05/1687 22/12/2005 2005 Available from: http://europa.eu/rapid/press-release_IP-05-1687_en.htm webcite
• [33]Kessler DA: Antibiotics and the meat we eat. New York Times, 27 March 2013. http://www.nytimes.com/2013/03/28/opinion/antibiotics-and-the-meat-we-eat.html webcite
• [34]Collignon P, Aarestrup FM, Irwin R, McEwen S: Human deaths and third-generation cephalosporin use in poultry. Europe. Emerg Infect Dis 2013, 19(8):1339-1340.
• [35]Overdevest I, Willemsen I, Rijnsburger M, Eustace A, Xu L, Hawkey P, et al.: Extended-spectrum beta-lactamase genes of Escherichia coli in chicken meat and humans, The Netherlands. Emerg Infect Dis 2011, 17(7):1216-1222.
• [36]Kluytmans JA K, Overdevest IT, Willemsen I, den Bergh MF K-v, van der Zwaluw K, Heck M, et al.: Extended-spectrum beta-lactamase-producing Escherichia coli from retail chicken meat and humans: comparison of strains, plasmids, resistance genes, and virulence factors. Clin Infect Dis 2013, 56(4):478-487.
• [37]Cosgrove SE: The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis 2006, 42(Suppl 2):S82-S89.
• [38]Casey JA, Curriero FC, Cosgrove SE, Nachman KE, Schwartz BS: High-density livestock operations, crop field application of manure, and risk of community-associated methicillin-resistant staphylococcus aureus infection in Pennsylvania. JAMA Intern Med 2013. epub ahead of print
• [39]van Loo I, Huijsdens X, Tiemersma E, de Neeling A, van de Sande-Bruinsma N, Beaujean D, et al.: Emergence of methicillin-resistant Staphylococcus aureus of animal origin in humans. Emerg Infect Dis 2007, 13(12):1834-1839.
• [40]Carlet J, Collignon P, Goldmann D, Goossens H, Gyssens IC, Harbarth S, et al.: Society's failure to protect a precious resource: antibiotics. Lancet 2011, 378(9788):369-371.
• [41]Jarlier V, Carlet J, McGowan J, Goossens H, Voss A, Harbarth S, et al.: Priority actions to fight antibiotic resistance: results of an international meeting. Antimicrob Resis Infect Contr 2012, 1(1):17. BioMed Central Full Text
• [42]Wenzel RP W, Edmond MB: Infection control: the case for horizontal rather than vertical interventional programs. Int J Infect Dis 2010, 14(Suppl 4):S3-S5.
• [43]Boyce JM: Environmental contamination makes an important contribution to hospital infection. J Hosp Infect 2007, 65(Suppl 2):50-54.
• [44]Pittet D, Hugonnet S, Harbarth S, Mourouga P, Sauvan V, Touveneau S, et al.: Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. Lancet 2000, 356(9238):1307-1312.
• [45]Afshari A, Schrenzel J, Ieven M, Harbarth S: Bench-to-bedside review: rapid molecular diagnostics for bloodstream infection - a new frontier? Crit Care 2012, 16(3):222. BioMed Central Full Text
• [46]Kurupati P, Teh BK, Kumarasinghe G, Poh CL: Identification of vaccine candidate antigens of an ESBL producing Klebsiella pneumoniae clinical strain by immunoproteome analysis. Proteomics 2006, 6(3):836-844.
• [47]McConnell MJ, Rumbo C, Bou G, Pachon J: Outer membrane vesicles as an acellular vaccine against Acinetobacter baumannii. Vaccine 2011, 29(34):5705-5710.
• [48]Liu Y, Egilmez NK, Russell MW: Enhancement of adaptive immunity to neisseria gonorrhoeae by local intravaginal administration of microencapsulated interleukin 12. J Infect Dis 2013. epub ahead of print
• [49]Feachem RG, Hogan RC, Merson MH: Diarrhoeal disease control: reviews of potential interventions. Bull World Health Organ 1983, 61(4):637-640.
• [50]MacDougall C, Polk RE: Antimicrobial stewardship programs in health care systems. Clin Microbiol Rev 2005, 18(4):638-656.
• [51]Gerber JS, Prasad PA, Fiks AG, Localio AR, Grundmeier RW, Bell LM, et al.: Effect of an outpatient antimicrobial stewardship intervention on broad-spectrum antibiotic prescribing by primary care pediatricians: a randomized trial. JAMA 2013, 309(22):2345-2352.
• [52]Nathwani D, Sneddon J, Malcolm W, Wiuff C, Patton A, Hurding S, et al.: Scottish antimicrobial prescribing group (SAPG): development and impact of the Scottish national antimicrobial stewardship programme. Int J Antimicrob Agents 2011, 38(1):16-26.
• [53]Talpaert MJ, Gopal Rao G, Cooper BS, Wade P: Impact of guidelines and enhanced antibiotic stewardship on reducing broad-spectrum antibiotic usage and its effect on incidence of Clostridium difficile infection. J Antimicrob Chemother 2011, 66(9):2168-2174.
• [54]Kaki R, Elligsen M, Walker S, Simor A, Palmay L, Daneman N: Impact of antimicrobial stewardship in critical care: a systematic review. J Antimicrob Chemother 2011, 66(6):1223-1230.
• [55]Furuya EY, Lowy FD: Antimicrobial-resistant bacteria in the community setting. Nat Rev Microbiol 2006, 4(1):36-45.
• [56]National Health Service UK 2013. [cited 20 October 2013]; Available from: http://www.nhs.uk/conditions/Clostridium-difficile/Pages/Introduction.aspx webcite
• [57]Sabuncu E, David J, Bernede-Bauduin C, Pepin S, Leroy M, Boelle PY, et al.: Significant reduction of antibiotic use in the community after a nationwide campaign in France, 2002–2007. PLoS Med 2009, 6(6):e1000084.
• [58]Bavestrello L, Cabello A, Casanova D: Impact of regulatory measures in the trends of community consumption of antibiotics in Chile. Rev Med Chil 2002, 130(11):1265-1272.
• [59]Swann M: Report of the joint committee on the use of antibiotics in animal husbandry and veterinary medicine [report]. London, United Kingdom: Her Majesty's Stationery Office; 1969.
• [60]Snitkin ES, Zelazny AM, Thomas PJ, Stock F, Henderson DK, Palmore TN, et al.: Tracking a hospital outbreak of carbapenem-resistant Klebsiella pneumoniae with whole-genome sequencing. Sci Transl Med 2012, 4(148):148ra16.
• [61]Kuhn T: The Structure of Scientific Revolutions. 1st edition. Chicago, IL: University of Chicago Press; 1962.
• [62]Hardin G: The tragedy of the commons. The population problem has no technical solution; it requires a fundamental extension in morality. Science 1968, 162(3859):1243-1248.
• [63]Gillespie SH: Antibiotic resistance in the absence of selective pressure. I J Antimicrob Agents 2001, 17(3):171-176.
• [64]Ghafur A, Mathai D, Muruganathan A, Jayalal JA, Kant R, Chaudhary D, et al.: The Chennai declaration: a roadmap to tackle the challenge of antimicrobial resistance. Indian J Cancer 2013, 50(1):71-73.
• [65]Chan M: Antimicrobial Resistance in the European Union and the World [speech]. 2012.
• [66]Centers for Disease Control and Prevention: Antimicrobial Resistance Threat Report. 2013. http://www.cdc.gov/drugresistance/threat-report-2013/ webcite
• [67]Science Ministers of the G8: G8 Science Ministers Statement. London, UK; 2013. https://www.gov.uk/government/publications/g8-science-ministers-statement-london-12-june-2013 webcite